Fluorophenibut (FGABA) is a synthetic research chemical structurally related to Phenibut, distinguished by a fluorine atom at the beta position. It is primarily studied for its effects on the GABAergic system, particularly its modulation of GABA-B receptors. FGABA is valued in laboratory settings for its enhanced lipophilicity, extended duration of action, and potential neuropharmacological significance in anxiety, cognition, and behavior-based models.

• Modified GABA Analog
  FGABA is a fluorinated analog of γ-aminobutyric acid (GABA), the brain’s primary inhibitory neurotransmitter. The fluorine atom enhances chemical properties that may make it more potent or longer lasting.

• Selective GABA-B Receptor Agonism
  It primarily interacts with GABA-B receptors, producing effects similar to other GABA analogs like Phenibut and Baclofen, making it relevant in receptor profiling studies.

• Non-Natural Compound
  FGABA does not occur naturally and is synthesized exclusively for laboratory research purposes. It is not intended for dietary, medical, or recreational use.

• Higher CNS Penetration
  The fluorine group increases the molecule’s ability to cross the blood-brain barrier, making it particularly useful in behavioral and central nervous system-related models.

• Research-Only Usage
  FGABA is sold and studied strictly for scientific research. It is unscheduled in most regions, though users are responsible for complying with local regulations.

Fluorophenibut is studied across multiple domains, from neuropharmacology to behavioral science. Researchers focus on its receptor interactions, structural modifications, and comparative efficacy against similar compounds.

• GABA-B Agonist Activity Analysis
  FGABA is a valuable tool for exploring GABA-B receptor pathways, useful in evaluating neuroinhibition, anxiolytic properties, and potential antidepressant models.

• Structure–Activity Relationship (SAR) Studies
  The presence of a fluorine atom makes FGABA ideal for SAR research, offering insights into how structural changes impact pharmacodynamics and receptor affinity.

• Nootropic and Cognitive Models
  FGABA is used in comparative studies examining its influence on memory, cognition, and attention in rodent models due to its resemblance to nootropic compounds.

• Behavioral Testing in Animal Models
  Rodents administered FGABA are observed for altered anxiety responses, social interaction, and locomotor activity, helping define its pharmacological footprint.

• Comparative Pharmacokinetics
  Researchers evaluate the metabolic breakdown, half-life, and bioavailability of FGABA versus Phenibut to determine advantages in molecular stability and action duration.

While FGABA and Phenibut share similar core structures, they are not identical. The fluorine substitution in FGABA introduces significant pharmacological and physicochemical differences, warranting its separate classification and research interest.

• Structural Fluorination
  FGABA contains a fluorine atom at the beta position of the butyric acid chain, a change that significantly alters its chemical behavior and potential receptor binding.

• Enhanced Potency and Duration
  Animal studies suggest that FGABA may produce stronger or longer-lasting effects compared to Phenibut, possibly due to improved receptor binding and metabolism resistance.

• Different Stability Profiles
  FGABA tends to be more chemically stable than Phenibut, making it a better candidate for long-term storage and experimental consistency.

• Legal and Regulatory Differences
  Phenibut is regulated or scheduled in some jurisdictions due to recreational misuse, while FGABA, being a novel analog, remains unscheduled in many regions (subject to change).

• Distinct Pharmacokinetics
  FGABA is thought to have a slower onset but longer duration, with differences in CNS distribution that make it useful for comparative neurochemical analysis.

To preserve the chemical stability and purity of Fluorophenibut, strict storage protocols must be followed. As with all research chemicals, improper handling can compromise study results or render the substance unusable.

• Temperature Control
  Store FGABA in a cool environment, ideally below 25°C (77°F). Higher temperatures may degrade its chemical structure over time.

• Low Humidity
  Exposure to moisture can lead to clumping, hydrolysis, or contamination. Always keep the compound sealed with a desiccant to maintain a dry environment.

• Protection from Light
  FGABA is light-sensitive, so it should be stored in an opaque or foil-lined container to prevent UV degradation.

• Airtight Containers
  Use resealable, airtight containers to minimize oxygen exposure and prevent cross-contamination with other lab compounds.

• Away from Reactants
  FGABA should not be stored near acids, bases, or volatile solvents that could initiate unintended chemical reactions.

• Clearly Labeled
  Always mark the compound with the name, molecular weight, batch number, and date of acquisition to maintain research integrity and compliance.

FGABA’s chemical makeup is simple yet effective, with molecular features that enhance its pharmacological behavior. Understanding its structural characteristics is essential for designing and interpreting research outcomes.

• Molecular Formula: C4H8FNO2
  Comprising carbon, hydrogen, fluorine, nitrogen, and oxygen, this formula is indicative of a fluorinated GABA analog.

• Molecular Weight: 121.11 g/mol
  Its relatively low molecular weight supports fast diffusion and bioavailability in biological models.

• Functional Groups
  FGABA includes a carboxylic acid group and a primary amine, allowing for interaction with biological transporters and receptors.

• Physical Appearance
  Typically appears as a white to off-white crystalline powder, indicating purity. The powder is fine and odorless, aiding in consistent laboratory handling.

• Solubility Characteristics
  FGABA is water-soluble and ethanol-soluble, making it versatile for solution-based dosing in lab settings.

• Chemical Stability
  It is stable under ambient laboratory conditions when stored correctly, with minimal risk of spontaneous degradation.

Fluorophenibut (FGABA) is currently classified as a research chemical and is generally unscheduled in most countries. This makes it legally accessible for scientific and analytical purposes, although the legality may vary by jurisdiction. Researchers are responsible for ensuring compliance with all applicable local, national, or institutional regulations.

• Unscheduled in Most Regions
  FGABA is not listed under international drug control treaties or scheduled under most national controlled substances acts. This makes it widely accessible for research.

• Not Approved for Human Consumption
  While legal for scientific use, FGABA is not approved for dietary, medicinal, or recreational use in any country. It should never be administered to humans or animals outside of approved studies.

• May Be Restricted by Analogue Laws
  In some jurisdictions, FGABA could fall under analogue legislation if it’s structurally similar to a controlled substance, like Phenibut. This could lead to legal ambiguity despite the absence of direct scheduling.

• Institutional Policy May Vary
  Academic and private research institutions may have internal rules governing which substances can be handled or ordered. Researchers should always confirm with their ethics board or compliance officer.

• Customs Clearance Not Guaranteed
  Even if legal, some customs departments may hold or reject packages containing chemical research products. Our packaging is designed to minimize this risk through discretion.

The shelf life of Fluorophenibut (FGABA) largely depends on how well it is stored. When kept under optimal conditions, FGABA remains chemically stable and research-ready for extended periods, making it ideal for long-term use in laboratories.

• Shelf Life: Up to 24 Months
  Properly sealed FGABA can remain viable for two years without significant loss of potency, provided storage guidelines are followed.

• Storage Conditions Critical
  To maintain this lifespan, FGABA should be stored in a cool, dry, and dark place. Failure to control temperature and humidity can reduce its usable duration.

• Desiccants Preserve Integrity
  Using desiccants inside the storage container helps reduce the risk of moisture-induced clumping or decomposition, which can compromise analytical results.

• Frequent Opening Reduces Life
  Each time the container is opened, exposure to air and moisture increases, gradually degrading the compound. Minimize handling or reseal quickly to preserve shelf life.

• Batch Numbers and Dating
  RC Plug provides batch-specific details and packaging dates to help researchers monitor product age and avoid using degraded material.

While FGABA and Phenibut share some pharmacological properties, they are not direct substitutes in research. FGABA offers a distinct chemical profile due to its fluorination, which alters its potency, pharmacokinetics, and possibly its safety profile.

• Structural Differences Impact Function
  The presence of a fluorine atom changes FGABA’s interaction with biological receptors, potentially altering its binding strength and metabolic breakdown.

• Potency May Be Higher
  Some studies suggest FGABA exhibits greater receptor affinity, which means researchers must adjust dosing when comparing results to Phenibut.

• Duration of Action Varies
  FGABA often shows a longer-lasting effect in vivo, making it better suited for extended time-course studies than Phenibut.

• Onset Times May Differ
  FGABA’s onset may be slightly slower due to altered lipophilicity and absorption rates. This must be accounted for in time-sensitive experimental protocols.

• Different Solubility and Formulation Profiles
  FGABA’s physicochemical properties may influence how it’s dissolved or administered in lab animals or in vitro systems, necessitating adjusted preparations.

Fluorophenibut (FGABA) is supplied by RC Plug as a high-purity, crystalline powder suitable for analytical and experimental use. This form is ideal for precise weighing, measuring, and solubility control during chemical testing.

• Fine Crystalline Powder
  FGABA is distributed as a uniform, white to off-white crystalline substance. The fine granulation allows for accurate measurements and easy dissolution in solvents.

• Odorless and Stable
  It has no detectable odor and is stable at room temperature, making it easy to handle during extended lab sessions.

• Packaged with Desiccants
  Each container includes desiccants to prevent moisture contamination, preserving chemical stability.

• Sealed in Resealable Bags
  The compound is vacuum-sealed and enclosed in laboratory-grade, resealable pouches for convenient storage and minimized exposure.

• Suitable for Various Research Models
  This form supports use in rodent models, in vitro cell cultures, or biochemical receptor binding assays, depending on the scope of the study.

The addition of a fluorine atom to the molecular backbone of FGABA significantly modifies its chemical and biological properties. Fluorination is a common strategy in medicinal chemistry used to improve drug-like properties such as metabolic stability, bioavailability, and receptor affinity.

• Increased Lipophilicity
  Fluorination enhances the compound’s ability to cross the blood-brain barrier, improving central nervous system availability and enabling more potent neurological effects.

• Improved Binding Affinity
  The electronegativity of fluorine can increase the molecular interaction with GABA-B receptors, potentially leading to stronger and more consistent receptor activation.

• Greater Metabolic Stability
  Fluorinated compounds tend to resist enzymatic breakdown, extending the compound’s active duration and allowing for longer-lasting effects in time-course experiments.

• Altered pKa and Solubility
  The presence of fluorine can shift acid-base characteristics and solubility in different solvents, which may require modified handling in some assay preparations.

• Reduced Oxidative Degradation
  FGABA is more chemically stable under standard lab conditions, reducing the risk of degradation during long-term storage or repeated handling.

Although FGABA is legal for research use, it is still a potent psychoactive analog that must be handled responsibly. Researchers are required to implement strict safety and procedural protocols to prevent exposure, misuse, or contamination.

• Use Personal Protective Equipment (PPE)
  Researchers should wear nitrile gloves, lab coats, and safety goggles when handling FGABA to prevent skin contact, accidental inhalation, or cross-contamination.

• Work in a Controlled Environment
  FGABA must be handled in a properly ventilated laboratory or under a fume hood. This reduces airborne particle exposure and ensures containment in case of spillage.

• Avoid Ingestion or Inhalation
  FGABA is strictly for analytical or experimental use. Inhalation or oral ingestion—even accidentally—can result in serious adverse effects due to its GABAergic potency.

• Label Clearly and Secure Proper Storage
  Containers should be properly labeled with the chemical name, hazard warnings, and date of receipt. Always store in locked cabinets to restrict unauthorized access.

• Follow Local Waste Disposal Protocols
  Any unused FGABA or contaminated materials (e.g., gloves, pipettes) should be disposed of according to hazardous waste guidelines to avoid environmental contamination.

• Document Handling Procedures
  Keep accurate logs of quantities used, dates of handling, and personnel involved to maintain lab accountability and traceability.

The onset of FGABA’s pharmacological activity can vary depending on the model, route of administration, and dosage. However, its structural design allows for relatively fast absorption and sustained receptor engagement, making it suitable for both acute and long-term studies.

• Onset: Approximately 1–2 Hours
  In most animal models, initial effects are observed within 60 to 120 minutes of administration, similar to Phenibut but with a potentially steadier buildup.

• Peak Plasma Concentration
  FGABA typically reaches peak activity at around 3–4 hours post-administration, allowing for a wide window to study behavioral or physiological responses.

• Extended Duration
  Depending on dosage and subject, effects may last from 8 to 14 hours, making it suitable for time-course or extended behavioral assays.

• Route-Dependent Onset
  Oral or intraperitoneal routes show differences in onset speed and bioavailability. Researchers should select methods based on experimental design.

• Slow Tolerance Development
  Unlike some GABA analogs, repeated use in animals appears to result in slower tolerance formation, which may support chronic-use models.

Yes, FGABA is soluble in water, which makes it easy to prepare in solution for laboratory applications. However, understanding its solubility profile is important to avoid formulation errors and ensure consistency in results.

• Water Soluble
  FGABA dissolves readily in distilled water, allowing researchers to prepare dosing solutions with precision. Always stir or sonicate for optimal dissolution.

• Compatible with Ethanol and DMSO
  It also dissolves well in ethanol and dimethyl sulfoxide (DMSO), making it compatible with a wide variety of solvent systems commonly used in pharmacological testing.

• Formulation Considerations
  Solutions should be prepared freshly or stored under refrigeration if not used immediately to avoid degradation or microbial growth.

• Concentration-Dependent Clarity
  Higher concentrations may require warming or extended mixing to achieve full solubility. Cloudiness may indicate impurities or improper mixing.

• pH Neutral Solutions
  FGABA typically dissolves into near-neutral pH ranges, minimizing the risk of irritation or unwanted reaction in biological models.

There is no universally accepted dosage for FGABA, as its application varies by experimental design, species, and administration method. However, literature and analog comparisons provide helpful dosing frameworks for responsible research.

• Start with Minimal Effective Doses
  It is advised to begin with the lowest possible concentration to determine threshold activity and minimize variable interference in new models.

• Typical Animal Study Range
  In rodent studies, researchers often test ranges between 10 mg/kg to 50 mg/kg depending on desired effects (e.g., anxiolytic vs. sedative outcomes).

• Adjust Based on Administration Route
  Oral doses often require higher quantities than intraperitoneal or intravenous due to bioavailability differences. Factor this into calculations.

• Account for Duration and Repetition
  FGABA’s extended half-life means repeated dosing must be spaced appropriately to avoid compounding effects or residual activity.

• Follow Ethical Guidelines
  Always conform to institutional animal care protocols and ethical review standards when determining dosage levels in animal subjects.

FGABA’s defining feature is its fluorinated structure, which sets it apart from other GABA-related compounds like Phenibut or Baclofen. This modification enhances its research utility by improving pharmacokinetics, stability, and binding dynamics.

• Structural Fluorination
  The fluorine atom increases lipophilicity, aiding in blood-brain barrier penetration and resulting in stronger CNS activity compared to non-fluorinated analogs.

• Extended Half-Life
  FGABA typically lasts longer in the body, providing a sustained window of effect, which is ideal for long-duration behavioral or receptor occupancy studies.

• Distinct Binding Profile
  Its receptor binding affinity may differ slightly from other GABA analogs, leading to more precise outcomes in receptor-specific assays.

• Improved Chemical Stability
  FGABA is less prone to oxidative or hydrolytic degradation, making it more shelf-stable and consistent across multiple study batches.

• Broader Solvent Compatibility
  The compound’s polarity and solubility allow it to be used in more diverse formulations than some traditional analogs, enhancing its versatility in lab settings.

Fluorophenibut (FGABA) holds a distinctive position among GABAergic agents due to its chemical enhancements, particularly fluorination. While it shares some core characteristics with Phenibut, Baclofen, and Gabapentin, its pharmacological behavior can differ considerably depending on the experimental context.

• Greater Blood-Brain Barrier Penetration
  FGABA’s fluorinated structure boosts its lipophilicity, potentially allowing for more efficient CNS access compared to Gabapentin or Baclofen.

• Longer Duration of Action
  Unlike Phenibut or Baclofen, FGABA often produces extended effects (up to 14 hours), which can reduce the frequency of dosing in long-term studies.

• Receptor Selectivity
  FGABA primarily targets GABA-B receptors, similar to Baclofen and Phenibut, but may bind more efficiently due to enhanced molecular interactions from fluorination.

• Better Chemical Stability
  Fluorination improves the shelf life and resistance to degradation, giving FGABA advantages in storage and repeat-experiment consistency.

• Reduced Peripheral Side Effects in Models
  Preliminary comparative studies suggest FGABA may show less peripheral GABAergic impact, though more research is needed to fully quantify this.